Evidence map›Paper›PMID 36470330›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2023

Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models.

Libor Kostka, Lenka Kotrchová, Eva Randárová, Carolina A Ferreira, Iva Malátová, Hye Jin Lee, Aeli P Olson, Jonathan W Engle, Marek Kovář, Weibo Cai and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Modular Software for Generating and Modeling Diverse Polymer Databases.Journal of chemical information and modeling · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Libor KostkaInstitute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic.
Lenka KotrchováInstitute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic.
Eva RandárováInstitute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic.
Carolina A FerreiraDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, United States.
Iva MalátováInstitute of Microbiology CAS, Laboratory of Tumor Immunology, Vídeňská 1083, Prague 4 14220, Czech Republic.
Hye Jin LeeDepartment of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, WI, United States.
Aeli P OlsonDepartments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, United States.
Jonathan W EngleDepartments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, United States.
Marek KovářInstitute of Microbiology CAS, Laboratory of Tumor Immunology, Vídeňská 1083, Prague 4 14220, Czech Republic.
Weibo CaiDepartment of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, WI, United States; Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, United States.
Milada ŠírováInstitute of Microbiology CAS, Laboratory of Tumor Immunology, Vídeňská 1083, Prague 4 14220, Czech Republic.
Tomáš EtrychInstitute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic. Electronic address: etrych@imc.cas.cz.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

Nanomedicines are considered next generation therapeutics with advanced therapeutic properties and reduced side effects. Herein, we introduce tailored linear and star-like water-soluble nanosystems as stimuli-sensitive nanomedicines for the treatment of solid tumors or hematological malignancies. The polymer carrier and drug pharmacokinetics were independently evaluated to elucidate the relationship between the nanosystem structure and its distribution in the body. Positron emission tomography and optical imaging demonstrated enhanced tumor accumulation of the polymer carriers in 4T1-bearing mice with increased tumor-to-blood and tumor-to-muscle ratios. Additionally, there was a significant accumulation of doxorubicin bound to various polymer carriers in EL4 tumors, as well as excellent in vivo therapeutic activity in EL4 lymphoma and moderate efficacy in 4T1 breast carcinoma. The linear nanomedicine showed at least comparable pharmacologic properties to the star-like nanomedicines regarding doxorubicin transport. Therefore, if multiple parameters are considered such as its optimized structure and simple and reproducible synthesis, this polymer carrier system is the most promising for further preclinical and clinical investigations.

Indexed as

Drug CarriersPolymersAnimalsCell Line, TumorDisease Models, AnimalDoxorubicinMiceNanomedicineDoxorubicinDrug CarriersPolymersBiodistributionCancerDrug deliveryHPMAPolymeric carriersPositron emission tomography

Identifiers

PMID36470330
PMCPMC9892306
OpenAlexW4310980439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.